Search results for "Ra-223"

showing 1 items of 1 documents

Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience

2019

Background: Treatment with radium-223 has been shown to increase survival and to delay skeletal events related to bone metastases of patients with metastatic Castration Resistant Prostate Cancer (mCRPC). This treatment has also proved to be well tolerated, and hematological toxicity, in particular anemia, represents the most represented adverse event. Materials and methods: We evaluated the hematologic toxicity of Ra-223 treatment in a real-life experience of 38 patients from two Italian cancer centers, with bone metastases from mCRPC. The main endpoint of the study was the evaluation of the efficacy and tolerability of treatment with radium-223, with greater reference to hematological toxi…

Radium-223medicine.medical_specialtyAnemiaUrology030232 urology & nephrologyNeutropenialcsh:RC870-923Ra-22303 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineAdverse effectCancerToxicitybusiness.industryProstatemedicine.diseaselcsh:Diseases of the genitourinary system. UrologyDiscontinuationOlderTolerabilityDocetaxel030220 oncology & carcinogenesisOriginal Articlebusinessmedicine.drugProstate International
researchProduct